- Home
- EXEL vs PODD Comparison
EXEL vs PODD Comparison
Compare EXEL & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | PODD |
|---|---|---|
| Founded | 1994 | 2000 |
| Country | United States | United States |
| Employees | N/A | 5400 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 10.3B |
| IPO Year | 2000 | 2007 |
Fundamental Metrics
Financial Performance| Metric | EXEL | PODD |
|---|---|---|
| Price | $50.11 | $147.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 21 |
| Target Price | $46.50 | ★ $341.48 |
| AVG Volume (30 Days) | ★ 2.7M | 1.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.95 | N/A |
| EPS | 0.79 | ★ 1.30 |
| Revenue | $452,477,000.00 | ★ $2,708,100,000.00 |
| Revenue This Year | $13.61 | $24.55 |
| Revenue Next Year | $13.13 | $19.18 |
| P/E Ratio | ★ $64.65 | $114.65 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $33.76 | $145.59 |
| 52 Week High | $51.63 | $354.88 |
Technical Indicators
Market Signals| Indicator | EXEL | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 63.40 | 27.99 |
| Support Level | $40.17 | N/A |
| Resistance Level | N/A | $205.95 |
| Average True Range (ATR) | 1.60 | 9.47 |
| MACD | 0.51 | -0.82 |
| Stochastic Oscillator | 82.66 | 5.00 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.